In this issue:
VRD vs. RD in new MM without intent for immediate autologous SCT
VRD with transplantation for MM
Carfilzomib, lenalidomide, dexamethasone in relapsed MM according to age
Low-dose lenalidomide less toxic with similar efficacy in relapsed/ refractory MM
Best combination for relapsed/refractory MM
Accelerated elotuzumab infusion with lenalidomide and dexamethasone in MM
Bortezomib-containing regimens for transplant-ineligible MM
Improved outcomes for patients treated at specialty MM clinic
Bendamustine, lenalidomide, dexamethasone second-line for relapsed/refractory MM
FIRST trial: outcomes for Asian participants
Please login below to download this issue (PDF)